FMP

FMP

Enter

PYXS - Pyxis Oncology, Inc.

Financial Summary of Pyxis Oncology, Inc.(PYXS), Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of t

photo-url-https://financialmodelingprep.com/image-stock/PYXS.png

Pyxis Oncology, Inc.

PYXS

NASDAQ

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

3.37 USD

-0.01 (-0.297%)

About

ceo

Dr. Lara S. Sullivan M.D., MBA

sector

Healthcare

industry

Biotechnology

website

https://www.pyxisoncology.com

exchange

NASDAQ

Description

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for tre...

CIK

0001782223

ISIN

US7473241013

CUSIP

747324101

Address

35 Cambridgepark Drive

Phone

617 221 9059

Country

US

Employee

51

IPO Date

Oct 8, 2021

Summary

CIK

0001782223

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

747324101

ISIN

US7473241013

Country

US

Price

3.37

Beta

1.33

Volume Avg.

500.5k

Market Cap

198.45M

Shares

-

52-Week

1.35-6.85

DCF

-0.26

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.46

P/B

-

Website

https://www.pyxisoncology.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest PYXS News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep